Skip to main content
SpringerLink
Log in

Endocrine Treatment of Advanced Breast Cancer

  • Chapter
Endocrine Therapy of Breast Cancer

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

The various endocrine therapies available in the treatment of breast cancer can be divided into four groups according to their demonstrated or suggested mode of biological action (table 1). These include ablative therapy, inhibitive therapy, additive therapy and competitive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dao TL: Ablation therapy for hormone-dependent tumours. Ann Rev Med 1972 (23): 1–18

    Article  PubMed  CAS  Google Scholar 

  2. Robin PE and Dalton GA: The role of major endocrine ablation. In: Stoll BA (ed) Breast cancer management - early and late. Chicago Year Book 1977: 147–156

    Google Scholar 

  3. Hayward J: Hormones and human breast cancer. Recent Results in Cancer Research vol 24 1970 Berlin, Heidelberg, New York: Springer Verlag

    Google Scholar 

  4. Dao TL: The value of adrenalectomy in patients with metastatic breast cancer. Surg Clin North Am 1978 (58): 801–807

    PubMed  CAS  Google Scholar 

  5. Hayward JL, Atkins HJB and Falconer MA: Clinical trials comparing transfrontal hypophysectmomy with adrenalectomy and with transethmoidal hypophysectomy. In: Joslin CAF, Gleave En (eds) The clinical management of advanced breast cancer. Cardiff: Alpha Omega Alpha 1970: 50–53

    Google Scholar 

  6. Stuart-Harris RC and Smith IE: Amiñoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 1984 (2): 189–204

    Article  Google Scholar 

  7. Semple CG, Thomson JA, Stark AN, McDonald M and Beatstoll GH: Trilostane and the normal hypothalamic-pituatory-adrenocorticol axis. Clin Endocrinol 1982 (17): 569–575

    Article  CAS  Google Scholar 

  8. Chamness GC, Asch RH and Paurstein CJ: Danazol binding and translocation of steroid receptors. Am J Obstet Gynecol 1980 (136): 426–429

    PubMed  CAS  Google Scholar 

  9. Menon M, Azhar S and Menon KMJ: Evidence that danazol inhibits gonadotropin-induced ovarian sterodogenesis at a point distal to gonadotropin receptor interaction and adonosine 31 5 - cyclic monophosphate formation. Am J Obstet Gynecol 1980 (136): 524–530

    PubMed  CAS  Google Scholar 

  10. Jenkin G: The mechanism of action of danazol. A novel steroid derivative. Aust N Z J Obstet Gynecol 1980 (2): 113–118

    Article  Google Scholar 

  11. Furr BJA and Nicholson RI: Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer. J Reprod Fertil 1982 (64): 529–539

    Article  PubMed  CAS  Google Scholar 

  12. Lippman M, Bolan G and Hoff K: The effects of estrogens and antiestrogens on hormone-responsive Human Breast Cancer in Long-Term Tissue Culture. Cancer Res 1976 (36): 4595–4601

    PubMed  CAS  Google Scholar 

  13. Zava DT and McGuire WL: Human breast cancer: Androgen action mediated by estrogen receptor. Science 1978 (199): 787–788

    Article  PubMed  CAS  Google Scholar 

  14. Nicholson RJ, Davies P and Griffiths K: Interaction of androgens with oestradiol-lytic mechanism. Eur J Cancer 1978 (14): 439–445

    PubMed  CAS  Google Scholar 

  15. Lober J, Rose C, Salimtschik M and Mouridsen HTL: Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand (suppl.) 1981 (101): 39–47

    Article  CAS  Google Scholar 

  16. Furr BJA and Jordan VC: The pharmacoloy and clinical uses of tamoxifen. Pharma Ther 1984 (25): 127–205

    Article  CAS  Google Scholar 

  17. Henderson IC and Canellos GP: Cancer of the breast. The past decade (First of two parts). New Engl J Med 1980 (302): 17–30

    Article  PubMed  CAS  Google Scholar 

  18. Robin PE and Dalton GA: The role of major endocrine ablation. In: Stoll BA (ed) Breast cancer management early and late. 1977: 147–153 London: Heineman

    Google Scholar 

  19. Hayward JL, Atkins and HJB Falconer MA: Clinical trials comparing transfrontal hypophysectomy with adrenalectomy and with transethmoidal hypophysectomy. In: Joslin CAF and Gleave EN (eds) The clinical management of advanced Breast Cancer. Cardiff: Alpha Omega Alpha 1970: 50–53

    Google Scholar 

  20. Roberts MM: A comparison of transethmoidal hypophysectomy, Yttrium 90 implant and adrenalectomy. In: Joslin CAF, Gleave EN (eds) The clinical management of advanced breast cancer Cardiff: Alpha Omega Alpha 1970: 54–62

    Google Scholar 

  21. Carter AC, Sedransk N and Kelley RM: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients: Report of the Cooperative Breast Cancer Group. JAMA 1977 (237): 2079–2085

    Article  PubMed  CAS  Google Scholar 

  22. Volk H, Deupree RH, Goldenberg IS, Wilden RC, Carabasi RA and Escher P: A dose response evaluation of delta-1-testolactone in advanced breast cancer. Cancer 1974 (9): 33–39

    Google Scholar 

  23. Talley RW, Haines CR and Waters MN: A dose-response evaluation of androgens in the treatment of metastatic breast cancer. Cancer 1973 (32): 315–320

    Article  PubMed  CAS  Google Scholar 

  24. Cavalli F, Goldhirsch A, Jungi WF, Martz G and ALbert P: Low- versus high-dose medroxyprogesterone acetate in the treatment of advanced breast cancer. Excerpta Medica international Congress Series 1982 (64): 224

    Google Scholar 

  25. Kamby c, Engelsman E, Nooy M, Rose C, Mouridsen HT, Sylvester R and Rotmenz N: Treatment of advanced breast cancer with medroxyprogesterone acetate: A phase III trial. 2nd European conference on clinical oncology and cancer nursing. Amsterdam 1983 abstract No 17–29

    Google Scholar 

  26. Mouridsen HT, Palshof T, Patterson J and Batterby L: Tamoxifen in advanced breasr cancer. Cancer Treatm Rev 1978 (5): 131–141

    Article  CAS  Google Scholar 

  27. McGuire WL: Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 1978 (5): 428

    PubMed  CAS  Google Scholar 

  28. Ward HWC: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two-dose levels. Br Med J 1973 (1): 13–14

    Article  PubMed  CAS  Google Scholar 

  29. Bratherton DG, Brown CH, Buchanan R, Halle V, Kingsley Piliers EM, Wheeler TK and Williams CJ: A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg b.d. vs 20 mg b.d. Br J Cancer 1984 (50): 199–205

    Article  PubMed  CAS  Google Scholar 

  30. Hoogstraten B, Fletcher WS, Gad-el-Mowla N, Maloney T, Altman SJ, yaughn CB and Faulker MA: Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: A Southwest Oncology Group Study. Cancer Res 1982 (42): 4788–4791

    PubMed  CAS  Google Scholar 

  31. Manni A and Pearson OH: Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treatm 1980 (64): 779–785

    CAS  Google Scholar 

  32. Pritchard KI, Thomson DB, Myers RE, Sutherland DJD, Mobbs BG, and Meakin JW: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treatm Rep 1980 (64): 787–796

    CAS  Google Scholar 

  33. Planting AST, Alexieva-Figusch J, Blonk-vd Wijst J and van Putten WLJ: Tamoxifen therapy in premenopausal women with metastatic. breats cancer. Cancer Treatm Rep 1985: 363–368

    Google Scholar 

  34. Wada T, Koyama H and Teresawa T: Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer Cancer Treatment Rep 1981 (65): 728–729

    CAS  Google Scholar 

  35. Ingle JN, Krook JE, Gree SJ, Kubista TP, Evanson LL, Almann DL, Chang MN, Bisel HF, Windschitl HE, TWito SI and Pfeifle DM: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986 (4): 178–185

    PubMed  CAS  Google Scholar 

  36. Bonneterre J, Coppens H, Mauric L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M and Cappelaere P: Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Eur J Cancer Clin Oncol 1985 (21): 1153–1158

    Article  PubMed  CAS  Google Scholar 

  37. Hindiey AC: Trilostane. A new hormonal agent in breast cancer. 3rd EORTC Breast Cancer Working Conf. Abstract no IX, 21, 1983

    Google Scholar 

  38. Coombs RC, Dearnaley D, Humphreys J, Gazet JC, Ford HT, Bash AG, Mashiter K and Powles TJ: Danazol treatment for advanced breast cancer. Eur J Cancer (suppl) 1980 (1): 83–88

    Google Scholar 

  39. Stewart HJ, Forrest APM and Gunn JM: The tamoxifen trial-a double-blind comparison with stilbestrol in postmenopausal women with advanced breast cancer. Eur J Cancer (suppl) 1980 (1): 83–88

    PubMed  Google Scholar 

  40. Beex L, Pieters G, Smals A, Koenders A, Benraad T and Kloppenberg P: Tamoxifen vs ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 1981 (65): 179–185

    PubMed  CAS  Google Scholar 

  41. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel JH, Kvals LK, Nichols WC, Creagan ET, Hahn RG, Rubin J and Frytag S: Randomized clinical trial of diethylstilbestrol vs tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1980 (304): 16–21

    Article  Google Scholar 

  42. Westerberg H: Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 1980 (64): 117–121

    PubMed  CAS  Google Scholar 

  43. Ingle JN, Creagan ET, Ahmann DL, Hahn RG, Green SJ, Rubin J and Edmonson JH: Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982 (5): 155–160

    Article  PubMed  CAS  Google Scholar 

  44. Morgan LR and Donley PJ: Tamoxifen versus megestrol acetate in breast cancer. Rev Endocr Rel Cancer (Suppl) 1981 (9): 301–310

    Google Scholar 

  45. Beretta G, Tabiadon D, Tedeschi L and Luporini G: Hormone therapy of advanced breast carcinoma: Comparative evaluation of tamoxifen citrate versus medroxyprogesterone acetate, In: Iacobelli S (ed) Role of Tamoxifen in Breast Cancer New York: Raven Press 1982: 113–120

    Google Scholar 

  46. Pannuti F, Martoni A, Fruet F, Burroni P, Canova N and Hall S: Oral high dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer. In: Iacobelli S (ed) The role of Tamoxifen in Breast Cancer. New York: Raven Press 1982: 85–92

    Google Scholar 

  47. Liptoarvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G and Shafik A: Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res (suppl) 1982 (42): 3434–3436

    Google Scholar 

  48. Smith IE, HArris AL, Morgan M, Gazet JC and McKinna SA: Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res (suppl 42) 1982: 3430–3433

    Google Scholar 

  49. Rose C and Mouridsen HT: Combined cytotoxic and endocrine therapy in advanced breast cancer. In: Bresciani F, King RBJ, Lippman ME, Namer M, Raynud JP (eds) Progress in cancer research and therapy. New York: Raven Press 1984: 269–286

    Google Scholar 

  50. Rose C and Mouridsen HT: Treatment of advanced breast cancer with tamoxifen. Recent Results Cancer Res. 1984 (91): 230–242

    PubMed  CAS  Google Scholar 

  51. Mouridsen HT, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Rorth M, Daehnfeldt JL and Rose C: Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstibestrol in advanced breast cancer in post-menopausal women. Eur J Cancer (suppl) 1980 (1): 107–110

    PubMed  Google Scholar 

  52. Tormey DC, Lippman MF, Edwards BE and Cassedy J: Evaluation of tamoxifen doses with and without fluoxymestrone in advanced breast cancer. Ann Intern Med 1983 (98): 139–144

    PubMed  CAS  Google Scholar 

  53. Heinonen E, Alanko A, Grohn P and Rissanen P: Tamoxifen versus nandrolone-decanoate in advanced breast cancer. 1st Scand Breast Cancer Sypmposium, Aarhus, Denmark 1982 Abstract 28

    Google Scholar 

  54. Mouridsen HT, Ellemann K, Mattson W, Palshof T: Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 1979 (63): 171–175

    PubMed  CAS  Google Scholar 

  55. Stewart JF, Rubens RD, King RJB, Minton MJ, Steiner R, Tong D, Winter PJ, Knoght RK and Hayward JL: Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Eur J Canc Clin Oncol 1982 (18): 1307–1314

    Article  CAS  Google Scholar 

  56. Rubens RD and Knight RK: The contribution of prednisolone (P) to primary endocrine therapy (PET) in advanced breast cancer. ASCO C 202, 1985

    Google Scholar 

  57. Milsted E, Habeshow T, Sangster G, Kaye S and Caiman K: Tamoxifen versus tamoxifen with aminoglutethimide in postmenopausal women with advanced breast cancer. 2nd Eur Conference on Clinical Oncology and Cancer Nursing. Amsterdam 1983. Abstract p. 186

    Google Scholar 

  58. Ingle JN, Green SJ, Ahmann Dl, Edmonson JH, Nichols WC, Frytag S and Rubin J: Progress report on two clinical trials in women with advanced breast cancer. Trial I: Tamoxifen versus tamoxifen plus aminoglutethimide; Trial II: Aminoglutethimide in patients with prior tamoxifen exposuncer Res (suppl) 1982 (42): 3461–3467

    Google Scholar 

  59. Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H, Andersen AP, Loft H, Dombernowsky P and Andersen KW: Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs tamoxifen plus aminoglutethimide and hydrocortisone. Breast Cancer Res and Treatm 1986. In press

    Google Scholar 

  60. Settatree RS: Bromocriptine, prolactine and nolvadex in advanced breast cancer. Revs Endocr Rel Cancer (suppl) 1980 (5): 63–70

    Google Scholar 

  61. Powles TJ, Ashley S and Ford HT: Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone and danazol used in combination or sequentially. Lancet 1984 (1): 1369–1373

    Article  PubMed  CAS  Google Scholar 

  62. Lippman ME: Efforts to comibine endocrine and chemotherapy in the management of breast cancer: Do two and two equal three? Breast Cancer Res and Treatm 1983 (3): 117–127

    Article  CAS  Google Scholar 

  63. Osborne CK: Combined chemo-endocrine therapy in breast cancer: A hypothesis. Breast Cancer Res and Treatm 1981 (1): 121–123

    Article  CAS  Google Scholar 

  64. Lippman ME, Cassidy J, Wesley M and Young RC: A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization. J Clin Oncol 1984 (2): 28–35

    PubMed  CAS  Google Scholar 

  65. Allegra JC: Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer. Semin Oncol (suppl) 1983 (2): 23–28

    Google Scholar 

  66. Paridaens R, Blonk van der Wijst J, Juline JP, Ferrazzi E, Claysse A, Heuson JC, Sylvester R and Rotmenz N: Cyclic combination chemotherapy preceded by estrogenic recruitment for treatment of advanced breast cancer. A phase II trial of the EORTC Breast Cancer Cooperative Group. 3rd EORTC Breast Cancer Working Conference 1983. Abstract n. 1, 10

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology ONA, The Finsen Institute, 49 Strandboulevarden, Copenhagen, Denmark

    H. T. Mouridsen

Authors
  1. H. T. Mouridsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Oncology, Ospedale San Giovanni, 6500, Bellinzona, Switzerland

    Franco Cavalli

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mouridsen, H.T. (1986). Endocrine Treatment of Advanced Breast Cancer. In: Cavalli, F. (eds) Endocrine Therapy of Breast Cancer. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71506-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71506-8_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71508-2

  • Online ISBN: 978-3-642-71506-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation